The company’s current proprietary product offering, approved by the FDA for commercial distribution on November 30, 2012, is the Shasta Genstrip blood glucose diagnostic test strip for at-home testing. Shasta Genstrip is a product conceived and designed by Shasta Technologies LLC, and fits into a diagnostic product niche and will sell into the world-wide self-test (home test) market that is expected to grow to $32 billion worldwide by 2017.
if DECN could capture 1% of that market yearly revenue would be 1% of 32b= $320 million (1% seems easy w a more accurate product 1/2 the price of market leader) generously say earnings were just 30%ish at 100 million w a conservative 10 p/e gives a market cap of $1b which is apx a 40 bagger from here... sorry if this is crude back of the envelope math many of you have all studied and dissected here, still trying to process what i am seeing, please make corrections.
Market Data 
Markets 
